![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Roche’s Neuromyelitis Optica Drug Enspryng Wins EU Approval
Roche’s Neuromyelitis Optica Drug Enspryng Wins EU Approval
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
June 29, 2021
Roche has secured European Commission approval for Enspryng (satralizumab) for treating adolescents and adults with neuromyelitis optica spectrum disorder (NMOSD), a central nervous system condition that can cause blindness, paralysis and painful spasms.
The drug, which the commission authorized as either a monotherapy or combined with immunosuppressive therapy, is administered subcutaneously every four weeks.
The approval was supported by two phase 3 studies which showed the drug offered “robust and sustained efficacy” in reducing the risk of disease relapse. Enspryng works by binding and blocking the interleukin-6 receptor that causes inflammation linked with NMOSD.
The treatment received FDA approval for the same indication in August.
Upcoming Events
-
21Oct